Immunocore Holdings plc (NASDAQ:IMCR) Expected to Post FY2028 Earnings of $1.85 Per Share

Immunocore Holdings plc (NASDAQ:IMCR) – Analysts at Capital One Financial raised their FY2028 EPS estimates for shares of Immunocore in a research report issued to clients and investors on Thursday, May 2nd. Capital One Financial analyst N. Quibria now forecasts that the company will post earnings of $1.85 per share for the year, up from their prior estimate of $1.66. The consensus estimate for Immunocore’s current full-year earnings is ($1.55) per share.

Other research analysts have also recently issued research reports about the company. Mizuho increased their target price on Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Canaccord Genuity Group lifted their price target on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research note on Thursday, February 29th. Leerink Partnrs reissued an “outperform” rating on shares of Immunocore in a research note on Monday, April 29th. Guggenheim reaffirmed a “buy” rating and set a $92.00 price objective on shares of Immunocore in a research note on Tuesday, April 23rd. Finally, SVB Leerink began coverage on Immunocore in a report on Monday, April 29th. They issued an “outperform” rating and a $74.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $80.92.

Immunocore Stock Down 1.4 %

IMCR stock opened at $61.04 on Monday. Immunocore has a 1-year low of $42.21 and a 1-year high of $76.98. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -52.62 and a beta of 0.92. The company has a current ratio of 3.80, a quick ratio of 3.77 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $61.10 and its 200 day moving average is $61.24.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The firm had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. During the same period in the prior year, the firm posted ($0.63) EPS. Immunocore’s revenue was up 22.4% on a year-over-year basis.

Hedge Funds Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently made changes to their positions in IMCR. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after purchasing an additional 426 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of Immunocore by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock valued at $181,000 after purchasing an additional 674 shares in the last quarter. JGP Global Gestao de Recursos Ltda. purchased a new position in shares of Immunocore during the fourth quarter valued at about $230,000. NEOS Investment Management LLC bought a new position in Immunocore in the fourth quarter worth about $262,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Immunocore by 26.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock worth $389,000 after buying an additional 1,572 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.